ClinicalTrials.gg
Active, not recruitingNCT06099782Updated Apr 8, 2026Results posted

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

A Phase 2 interventional study of Pembrolizumab (+) Berahyaluronidase alfa and Pembrolizumab in Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Melanoma, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 45 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
42nd of 127
147 · median 65
Started
2023
with 7 others
Phase 2
65 of 127
20 open now
Primary completion
2025-04
later than 10 of 47 live
Registered
103rd of 127
by date
Lead sponsor
27 of 127
Merck Sharp & Dohme LLC

Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 42nd largest by enrollment, is one of 8 that started in 2023, is one of 65 in phase 2, reaches primary completion later than 10 of the 47 other live ones, and was the 103rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475] administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a - or cytologically-confirmed early stage or advanced/ solid tumor by pathology report and meet the following conditions based on tumor type:

    • Surgically resected Stage IIB and IIC (pathological or clinical), or III cutaneous melanoma per American Joint Committee on Cancer (AJCC) eighth edition.
    • Surgically resected renal cell carcinoma (RCC) with intermediate-high or high risk of recurrence as defined by the Fuhrman grading status.
    • Stage IV non-small cell lung cancer (NSCLC) per AJCC eight edition, with an anti-programmed cell death ligand 1 () tumor proportion score (TPS) ≥50% determined using the Dako PD-L1 immunohistochemistry (IHC) 22C3 pharmDx diagnostic kit, and confirmation that epidermal growth factor receptor (EGFR-), anaplastic lymphoma kinase (ALK-), or c-ros oncogene 1 (ROS1)- directed therapy is not indicated as primary therapy.
  • Has a of at least 3 months.
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load before randomization.
  • Participants with history of virus (HCV) infection are eligible if have completed curative antiviral therapy at least 4 weeks before randomization and HCV viral load is undetectable at screening.
  • Has an (ECOG) performance status of 0 to 1 assessed within 3 days before the start of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Non-small cell lung cancer (NSCLC) participants with a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.
  • Melanoma participants with ocular, mucosal, or conjunctival melanoma.
  • Renal Cell Carcinoma (RCC) participants who have had major surgery, other than nephrectomy, within 12 weeks before randomization.
  • Has received prior radiotherapy for RCC.
  • RCC participants who have residual thrombus post nephrectomy in the vena renalis or vena cava.
  • Has received prior therapy with an anti-programmed cell death 1 protein (), PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
  • Has received prior systemic anticancer therapy including agents within 4 weeks before randomization.
  • Has received a live or within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
  • Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring .
  • Received prior systemic anticancer therapy for their NSCLC. Note: Prior treatment with or adjuvant therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.
  • Received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention.
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
  • Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of therapy within 7 days prior the first dose of study medication.
  • Has known additional that is progressing or has required active treatment within the past 3 years.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Has active disease that has required systemic treatment in the past 2 years.
  • Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Has active infection requiring systemic therapy.
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
  • Has history of allogeneic tissue/solid organ transplant corticosteroids.
  • Has severe (≥Grade 3) to pembrolizumab and/or any of its .
  • Has not adequately recovered from major surgery or have ongoing surgical complications.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Arm A: Pembrolizumab (+) Berahyaluronidase alfa SC →Pembrolizumab IV

    In the Treatment Crossover Period: participants will first receive pembrolizumab (+) berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles. After completion of the Treatment Crossover Period, participants will enter the Treatment Continuation Period where they will receive their preferred intervention for up to 17 21-day cycles (up to \~1 year) for renal cell carcinoma (RCC) and melanoma, and for up to 35 21-day cycles (up to \~2 years) for non-small cell lung cancer (NSCLC).

    Biological: Pembrolizumab (+) Berahyaluronidase alfa · Biological: Pembrolizumab

  • Active comparator
    Arm B: Pembrolizumab IV→pembrolizumab (+) berahyaluronidase alfa SC

    In the Treatment Crossover Period: participants will first receive pembrolizumab IV for three 21-day cycles, followed by pembrolizumab (+) berahyaluronidase alfa SC for three 21-day cycles. After completion of the Treatment Crossover Period, participants will enter the Treatment Continuation Period where they will receive their preferred intervention for up to 17 21-day cycles (up to \~1 year) for renal cell carcinoma (RCC) and melanoma, and for up to 35 21-day cycles (up to \~2 years) for non-small cell lung cancer (NSCLC).

    Biological: Pembrolizumab (+) Berahyaluronidase alfa · Biological: Pembrolizumab

Interventions

  • BiologicalPembrolizumab (+) Berahyaluronidase alfa

    Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.

    Also known as: MK-3475A

  • BiologicalPembrolizumab

    Administered via IV infusion

    Also known as: MK-3475, KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 1

    The PPQ is an instrument that has been developed from participant interviews and includes questions to evaluate directly from participants their preference regarding mode of administration, as well as the strength of the preference, and the reason for the preference. The PPQ does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the PPQ evaluates participants' preferred method of administration with response options of IV, SC or "no preference". As pre-specified by the protocol, the percentage of participants who preferred SC administration (participant preference rate \[PPR\]) was reported out of all randomized participants who received all 3 doses of Pembrolizumab IV and Pembrolizumab SC during treatment crossover period and answered at least question 1 of the PPQ on Cycle 6 Day 1 (Day 106).

    Time frame: Day 106

Secondary outcomes

  1. Percentage of Participants Who Preferred SC Administration According to Most Frequent Reasons of Preference As Assessed by PPQ Question 3

    The PPQ is an instrument that has been developed from patient interviews and includes questions to evaluate directly from participants their preference regarding mode of administration, as well as the strength of the preference, and the reason for the preference. PPQ Question 3 evaluated 2 main reasons for participants' preference for one of the administration methods (SC or IV), with response options including "feels less emotionally distressing", "requires less time in the clinic", and "lower level injection-site pain". As pre-specified by the supplemental statistical analysis plan (sSAP), the most frequent reasons for preferring SC administration as assessed by PPQ Question 3 were reported among all participants preferring SC in each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.

    Time frame: Day 106

  2. Percentage of Participants That Were Satisfied or Dissatisfied With the SC Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) Question 1

    The TASQ SC is a 12-item questionnaire that asks questions regarding different aspects of participants' satisfaction with SC administration, experiences related to administration, convenience, and time. The TASQ SC does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the TASQ SC evaluates participants' satisfaction or dissatisfaction with SC administration. As pre-specified by the sSAP, the percentage of participants was reported for each response to TASQ-SC Question 1 according to level of satisfaction, for each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.

    Time frame: Up to approximately Day 106

  3. Percentage of Participants That Were Satisfied or Dissatisfied With the IV Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire -Intravenous (TASQ-IV) Question 1

    The TASQ IV is a 12-item questionnaire that asks questions regarding different aspects of participants' satisfaction with IV administration, experiences related to administration, convenience, and time. The TASQ IV does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the TASQ IV evaluates participants' satisfaction or dissatisfaction with IV administration. As pre-specified by the sSAP, the percentage of participants was reported for each response to TASQ-IV Question 1 according to level of satisfaction, for each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.

    Time frame: Up to approximately Day 106

  4. Percentage of Participants Who Chose Pembrolizumab (+) Berahyaluronidase Alfa SC or Pembrolizumab IV for the Treatment Continuation Period on the Participant Choice Questionnaire

    The Participant Choice Questionnaire offered participants SC or IV treatment administration choices for the Treatment Continuation Period of the study, and was administered on Day 106 after study intervention administration. As pre-specified by the sSAP, the percentage of participants who chose either SC or IV treatment for the Treatment Continuation Period in the study was reported out of all randomized participants who chose to receive treatment intervention in the Treatment Continuation Period.

    Time frame: Day 106

  5. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified by the protocol, the number of participants who experience an AE will be reported for the overall study according to treatment arm, defined as a treatment sequence arm in the protocol (i.e., "Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV" and "Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC").

    Time frame: Up to ~27 months

  6. Number of Participants Who Discontinue Study Drug Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified by the protocol, the number of participants who discontinue study drug due to an AE will be reported for the overall study according to treatment arm, defined as a treatment sequence arm in the protocol (i.e., "Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV" and "Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC").

    Time frame: Up to ~24 months

07

Results

Posted Apr 8, 2026

Participant flow

Treatment Crossover Period 1: Cycles 1-3
Participant flow — Treatment Crossover Period 1: Cycles 1-3
MilestoneArm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
Started7176
Received pembrolizumab (+) berahyaluronidase alfa sc710
Received pembrolizumab iv076
Completed6570
Not completed66
Withdrew: Death43
Withdrew: Ongoing23
Treatment Crossover Period 2: Cycles 4-6
Participant flow — Treatment Crossover Period 2: Cycles 4-6
MilestoneArm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
Started6570
Received pembrolizumab (+) berahyaluronidase alfa sc070
Received pembrolizumab iv650
Completed5759
Not completed811
Withdrew: Death23
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01
Withdrew: Ongoing57
Treatment Continuation Period
Participant flow — Treatment Continuation Period
MilestoneArm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
Started5759
Completed00
Not completed5759
Withdrew: Death13
Withdrew: Ongoing5656

Outcome measures

PrimaryPercentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 1

The PPQ is an instrument that has been developed from participant interviews and includes questions to evaluate directly from participants their preference regarding mode of administration, as well as the strength of the preference, and the reason for the preference. The PPQ does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the PPQ evaluates participants' preferred method of administration with response options of IV, SC or "no preference". As pre-specified by the protocol, the percentage of participants who preferred SC administration (participant preference rate \[PPR\]) was reported out of all randomized participants who received all 3 doses of Pembrolizumab IV and Pembrolizumab SC during treatment crossover period and answered at least question 1 of the PPQ on Cycle 6 Day 1 (Day 106).

Time frame:
Day 106
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 1
Percentage of ParticipantsFull Analysis Set
Percentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 165.3
SecondaryPercentage of Participants Who Preferred SC Administration According to Most Frequent Reasons of Preference As Assessed by PPQ Question 3

The PPQ is an instrument that has been developed from patient interviews and includes questions to evaluate directly from participants their preference regarding mode of administration, as well as the strength of the preference, and the reason for the preference. PPQ Question 3 evaluated 2 main reasons for participants' preference for one of the administration methods (SC or IV), with response options including "feels less emotionally distressing", "requires less time in the clinic", and "lower level injection-site pain". As pre-specified by the supplemental statistical analysis plan (sSAP), the most frequent reasons for preferring SC administration as assessed by PPQ Question 3 were reported among all participants preferring SC in each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.

Time frame:
Day 106
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Preferred SC Administration According to Most Frequent Reasons of Preference As Assessed by PPQ Question 3
Percentage of ParticipantsArm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
Requires less time in the clinic59.466.7
Feels more comfortable during administration68.857.8
Lower level of injection-site pain31.342.2
Feels less emotionally distressing21.920.0
SecondaryPercentage of Participants That Were Satisfied or Dissatisfied With the SC Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) Question 1

The TASQ SC is a 12-item questionnaire that asks questions regarding different aspects of participants' satisfaction with SC administration, experiences related to administration, convenience, and time. The TASQ SC does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the TASQ SC evaluates participants' satisfaction or dissatisfaction with SC administration. As pre-specified by the sSAP, the percentage of participants was reported for each response to TASQ-SC Question 1 according to level of satisfaction, for each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.

Time frame:
Up to approximately Day 106
Reported as:
Number · Percentage of Participants
Percentage of Participants That Were Satisfied or Dissatisfied With the SC Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) Question 1
Percentage of ParticipantsArm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
Very satisfied71.955.7
Satisfied26.324.6
Neither satisfied nor dissatisfied0.011.5
Dissatisfied1.86.6
Missing0.01.6
SecondaryPercentage of Participants That Were Satisfied or Dissatisfied With the IV Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire -Intravenous (TASQ-IV) Question 1

The TASQ IV is a 12-item questionnaire that asks questions regarding different aspects of participants' satisfaction with IV administration, experiences related to administration, convenience, and time. The TASQ IV does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the TASQ IV evaluates participants' satisfaction or dissatisfaction with IV administration. As pre-specified by the sSAP, the percentage of participants was reported for each response to TASQ-IV Question 1 according to level of satisfaction, for each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.

Time frame:
Up to approximately Day 106
Reported as:
Number · Percentage of Participants
Percentage of Participants That Were Satisfied or Dissatisfied With the IV Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire -Intravenous (TASQ-IV) Question 1
Percentage of ParticipantsArm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
Very satisfied45.662.3
Satisfied33.329.5
Neither satisfied nor dissatisfied17.54.9
Dissatisfied1.81.6
Missing1.81.6
SecondaryPercentage of Participants Who Chose Pembrolizumab (+) Berahyaluronidase Alfa SC or Pembrolizumab IV for the Treatment Continuation Period on the Participant Choice Questionnaire

The Participant Choice Questionnaire offered participants SC or IV treatment administration choices for the Treatment Continuation Period of the study, and was administered on Day 106 after study intervention administration. As pre-specified by the sSAP, the percentage of participants who chose either SC or IV treatment for the Treatment Continuation Period in the study was reported out of all randomized participants who chose to receive treatment intervention in the Treatment Continuation Period.

Time frame:
Day 106
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Chose Pembrolizumab (+) Berahyaluronidase Alfa SC or Pembrolizumab IV for the Treatment Continuation Period on the Participant Choice Questionnaire
Percentage of ParticipantsParticipants Continuing Treatment in Continuation Period
SC68.0
IV32.0
SecondaryNumber of Participants Who Experience an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified by the protocol, the number of participants who experience an AE will be reported for the overall study according to treatment arm, defined as a treatment sequence arm in the protocol (i.e., "Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV" and "Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC").

Time frame:
Up to ~27 months

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinue Study Drug Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified by the protocol, the number of participants who discontinue study drug due to an AE will be reported for the overall study according to treatment arm, defined as a treatment sequence arm in the protocol (i.e., "Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV" and "Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC").

Time frame:
Up to ~24 months

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab (+) Berahyaluronidase Alfa SC10/141 (7.1%)20/141 (14.2%)99/141 (70.2%)
Pembrolizumab IV6/141 (4.3%)22/141 (15.6%)63/141 (44.7%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventPembrolizumab (+) Berahyaluronidase Alfa SCPembrolizumab IV
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/1413/141
PneumoniaInfections and infestations3/1414/141
DiarrhoeaGastrointestinal disorders0/1412/141
Pleural effusionRespiratory, thoracic and mediastinal disorders1/1412/141
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1412/141
Acute myocardial infarctionCardiac disorders1/1410/141
Myocardial infarctionCardiac disorders0/1411/141
VertigoEar and labyrinth disorders0/1411/141
Adrenal insufficiencyEndocrine disorders1/1411/141
HypophysitisEndocrine disorders1/1410/141
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPembrolizumab (+) Berahyaluronidase Alfa SCPembrolizumab IV
DiarrhoeaGastrointestinal disorders21/1416/141
HypothyroidismEndocrine disorders20/14114/141
PruritusSkin and subcutaneous tissue disorders20/1419/141
Alanine aminotransferase increasedInvestigations11/14113/141
FatigueGeneral disorders12/1418/141
ArthralgiaMusculoskeletal and connective tissue disorders12/1415/141
RashSkin and subcutaneous tissue disorders12/1414/141
AstheniaGeneral disorders11/1417/141
AnaemiaBlood and lymphatic system disorders10/1418/141
Injection site painGeneral disorders10/1410/141

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SCTotal
Mean59.7 ± 11.863.2 ± 12.561.5 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SCTotal
Female292857
Male424890
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SCTotal
Hispanic or Latino262753
Not Hispanic or Latino374077
Unknown or Not Reported8917
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IVArm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SCTotal
American Indian or Alaska Native000
Asian358
Native Hawaiian or Other Pacific Islander000
Black or African American022
White5860118
More than one race202
Unknown or Not Reported8917
08

Study locations

45 sites
09

References and documents

Publications

  • Casarini IA, Kowalski DM, Caglevic C, Karaca Yayla B, Sumbul AT, Yanez Weber P, Yanzi Castilla AN, Bylicki O, Takagi T, McQuarrie K, Saraf S, Arunachalam A, Bhagwati N, Cohen G. Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study. JCO Oncol Pract. 2026 Jun 3:OP2501248. doi: 10.1200/OP-25-01248. Online ahead of print. PubMed 42234938 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Apr 2025, 15 months.

Results were first posted in Apr 2026, 11 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 15 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 25, 2023
StartActual
Dec 26, 2023
Primary completionActual
Apr 9, 2025
CompletionEst.
Feb 15, 2027
Results first posted
Apr 8, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06099782
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Dec 26, 2023
Primary completion
Apr 9, 2025
Completion
Feb 15, 2027 (estimated)
Results posted
Apr 8, 2026
Last update
Apr 8, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion